Computational and Structural Biotechnology Journal (Jan 2021)

Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis

  • Abby C. Lee,
  • Wei Tse Li,
  • Lauren Apostol,
  • Jiayan Ma,
  • Pam R. Taub,
  • Eric Y. Chang,
  • Mahadevan Rajasekaran,
  • Weg M. Ongkeko

Journal volume & issue
Vol. 19
pp. 3755 – 3764

Abstract

Read online

Background: COVID-19 has infected over 35 million people worldwide and led to over 1 million deaths. Several risk factors that increase COVID-19 severity have emerged, including age and a history of cardiovascular disease, hypertension, or kidney disease. However, a number of outstanding questions persist, including whether the above comorbidities correlate with increased mortality from COVID-19 or whether age is a significant confounding variable that accounts for the observed relationship between COVID-19 severity and other comorbidities. Methods and Findings: We conducted a systematic review and meta-analysis of studies documenting COVID-19 patients with hypertension, cardiovascular disease, cerebrovascular disease, or chronic kidney disease. We classified COVID-19 cases into severe/non-severe or deceased/surviving and calculated the odds ratio (OR) for each of the four comorbidities in these cohorts. 36 studies, comprising 22,573 patients, are included in our meta-analysis. We found that hypertension is the most prevalent comorbidity in deceased COVID-19 patients (55.4%; CI: 49.4–61.3%), followed by cardiovascular disease (30.7%; CI: 22.6–38.8%), cerebrovascular disease (13.4%; CI: 9.12–19.2%), then chronic kidney disease (9.05%; CI: 5.57–15.0%). The risk of death is also significantly higher for patients with these comorbidities, with the greatest risk factor being chronic kidney disease (OR: 8.86; CI: 5.27–14.89), followed by cardiovascular disease (OR: 6.87; CI: 5.56–8.50), hypertension (OR: 4.87; CI: 4.19–5.66), and cerebrovascular disease (OR: 4.28; CI: 2.86–6.41). These risks are significantly higher than previously reported, while correlations between comorbidities and COVID-19 severity are similar to previously reported figures. Using meta-regression analysis with age as a moderating variable, we observed that age contributes to the observed risks but does not explain them fully. Conclusions: In this meta-analysis, we observed that cardiovascular, cerebrovascular, and kidney-related comorbidities in COVID-19 significantly contributes to greater risk of mortality and increased disease severity. We also demonstrated that age may not be a confounder to these associations.

Keywords